NASDAQ:MBRX Moleculin Biotech Q2 2024 Earnings Report $2.41 -0.03 (-1.15%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Moleculin Biotech EPS ResultsActual EPS-$55.75Consensus EPS -$52.50Beat/MissMissed by -$3.25One Year Ago EPSN/AMoleculin Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoleculin Biotech Announcement DetailsQuarterQ2 2024Date8/13/2024TimeN/AConference Call DateWednesday, August 14, 2024Conference Call Time8:00AM ETUpcoming EarningsMoleculin Biotech's Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Moleculin Biotech Earnings HeadlinesIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits2 hours ago | globenewswire.comMoleculin Biotech Secures Hong Kong Patent for Annamycin Method Ahead of Phase 3 Clinical Data ReleaseMay 8, 2026 | quiverquant.comQNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Central banks bought a record 863 tonnes in 2025 alone - and one small-cap explorer in Nevada's Walker Lane Belt may be positioned to benefit. Sitting 18 miles north of Tonopah in the same district that produced over 15 million ounces at Kinross Gold's Round Mountain Mine, this explorer carries historic drill intercepts of 30 meters at 2.5 g/t gold and surface samples exceeding 100 g/t. With a market cap under $15 million and drills ready to turn in H2 2026, the window may be narrow.May 12 at 1:00 AM | Wall Street Logic (Ad)Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of AnnamycinMay 8, 2026 | globenewswire.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Sees Large Growth in Short InterestMay 2, 2026 | americanbankingnews.comMoleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 24, 2026 | markets.businessinsider.comSee More Moleculin Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email. Email Address About Moleculin BiotechMoleculin Biotech (NASDAQ:MBRX) is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need. The company’s pipeline includes multiple product candidates at various stages of development. WP1066 is an immunotherapeutic compound designed to inhibit the STAT3 signaling pathway, which is implicated in the growth and survival of certain brain tumors and other malignancies. Annamycin is an anthracycline derivative engineered to overcome resistance mechanisms in acute myeloid leukemia (AML) with the goal of improving safety and efficacy. In addition, Moleculin is advancing WP1220, a broad-spectrum antiviral candidate targeting poxviruses and coronaviruses through inhibition of viral replication. Headquartered in Houston, Texas, Moleculin Biotech collaborates with academic institutions and contract research organizations to conduct its preclinical and clinical studies. The company’s development programs include Phase 1 and Phase 2 clinical trials in the United States, with plans to initiate additional studies in international markets as regulatory approvals are secured. Such partnerships and trial sites enable Moleculin to advance its candidates efficiently through the clinical development pathway. Founded in 2012, Moleculin Biotech is led by Walter Klemp, President and Chief Executive Officer, a veteran in the biotech industry with experience in drug development and corporate strategy. Under his leadership, the company continues to expand its research capabilities and global trial network, aiming to bring its innovative therapies to patients with critical oncological and viral diseases.View Moleculin Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles On Holdings Sets Up for Marathon Rally: New Highs Are ComingMP Materials Is Quietly Building a Rare Earth PowerhouseUbiquiti’s Uptrend Can Continue, But Don’t Rush to Buy ItAI Demand Fuels Strong Q1 Earnings for Constellation EnergyMercadoLibre Boldly Invests in Growth: Discount DeepensManic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderMeta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
